Efgartigimod in refractory autoimmune myasthenia gravis.

Introduction/aims: Efgartigimod, a neonatal Fc-receptor inhibitor, has recently been approved as treatment for myasthenia gravis (MG). In this retrospective cohort study, we aimed to systematically assess short- and long-term effectiveness of efgartigimod in patients with refractory MG.

Methods: Sixteen patients with refractory autoimmune acetylcholine receptor MG were treated with efgartigimod.

The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.

Pyridostigmine is the most commonly used drug in the symptomatic treatment of myasthenia gravis (MG); however, research into its effectiveness and side effects is scarce. The aim of this study was to assess the effectiveness, prevalence of side effects and net benefit of pyridostigmine. All MG patients participating in the Dutch-Belgian myasthenia patient registry were included.